539730 FREDUN

Fredun Pharmaceuticals Share Price

 

 

Start SIP in FREDUN

Start SIP
Fredun Pharmaceuticals live price: ₹1648. It opened at ₹1,690 vs previous close ₹1,678; intraday high/low: ₹1,690/₹1,602. The 50 & 200 DMA stand at ₹1,634.38/₹1,405.89.

Fredun Pharmaceuticals Performance

  • Low
  • ₹1,602
  • High
  • ₹1,690
  • 52 Week Low
  • ₹635
  • 52 Week High
  • ₹1,999
  • Open Price₹1,690
  • Previous Close₹1,678
  • Volume8,205
  • 50 DMA₹1,634.38
  • 100 DMA₹1,576.66
  • 200 DMA₹1,405.89

Investment Returns

  • Over 1 Month -9.35%
  • Over 3 Month + 4.21%
  • Over 6 Month + 35.98%
  • Over 1 Year + 143.05%

Smart Investing Starts Here Start SIP with Fredun Pharmaceuticals for Steady Growth!

Invest Now

Fredun Pharmaceuticals Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.

  • P/E Ratio
  • 22.9
  • PEG Ratio
  • 0.3
  • Market Cap Cr
  • 778
  • P/B Ratio
  • 4.6
  • Average True Range
  • 105.91
  • EPS
  • -
  • Dividend Yield
  • 0
  • MACD Signal
  • -4.86
  • RSI
  • 49.22
  • MFI
  • 32.69

Fredun Pharmaceuticals Financials

Fredun Pharmaceuticals Technicals

EMA & SMA

Current Price
₹1,648.00
-30.1 (-1.79%)
pointer
  • Bearish Moving Average 4
  • Bullish Moving Average 12
  • 20 Day
  • ₹1,639.15
  • 50 Day
  • ₹1,634.38
  • 100 Day
  • ₹1,576.66
  • 200 Day
  • ₹1,405.89

Resistance and Support

1641.58 Pivot Speed
  • R3 1,769.17
  • R2 1,729.58
  • R1 1,681.17
  • S1 1,593.17
  • S2 1,553.58
  • S3 1,505.17

Ratings

Master Rating

EPS Strenth

Price Strength

Buyer Demand

Group Rank

Fredun Pharmaceuticals has an operating revenue of Rs. 589.35 Cr. on a trailing 12-month basis. An annual revenue growth of 31% is outstanding, Pre-tax margin of 6% is okay, ROE of 14% is good. The company has a reasonable debt to equity of 7%, which signals a healthy balance sheet. The stock from a technical standpoint is trading close to its 50DMA and comfortably placed above its 200DMA, around 23% above 200DMA. It needs to take support around the 50 DMA level to continue further upside move. It has recently broken out of a base in its weekly chart but failed to keep its momentum and is trading around -8% from the pivot point. From an O'Neil Methodology perspective, the stock has an EPS Rank of 98 which is a GREAT score indicating consistency in earnings, a RS Rating of 95 which is GREAT indicating the outperformance as compared to other stocks, Buyer Demand at B+ which is evident from recent demand for the stock, Group Rank of 51 indicates it belongs to a fair industry group of Medical-Diversified and a Master Score of A is the best. Overall, the stock has great fundamentals and technical strength to stay in momentum.

Disclaimer: This stock analysis report is algorithmically generated for informational purposes only and should not be considered as a buy or sell recommendation.

View More

Fredun Pharmaceuticals Corporate Actions - Bonus, Splits, Dividends

Date Purpose Remarks
2026-02-09 Quarterly Results
2025-11-08 Quarterly Results
2025-09-25 Preferential Issue of shares & Others To consider 1. Issue Of Warrants. alia, to consider a proposal for fund raising up to Rs.120 crores by way of further public offer, rights issue, debt issue, preferential issue or any other method.
2025-07-30 Quarterly Results
2025-05-30 Audited Results & Dividend
Date Purpose Remarks
2025-09-23 FINAL Rs.0.70 per share(7%)Dividend
2024-09-23 FINAL Rs.0.70 per share(7%)Final Dividend
2023-09-22 FINAL Rs.0.70 per share(7%)Final Dividend
2022-09-15 FINAL Rs.0.70 per share(7%)Final Dividend
View Fredun Pharmaceuticals Dividend History Arrow

Fredun Pharmaceuticals F&O

Fredun Pharmaceuticals Shareholding Pattern

43.06%
1.06%
1.4%
45.62%
8.86%

About Fredun Pharmaceuticals

  • NSE Symbol
  • FREDUN
  • BSE Symbol
  • 539730
  • Managing Director & CFO
  • Mr. Fredun Medhora
  • ISIN
  • INE194R01017

Similar Stocks to Fredun Pharmaceuticals

Fredun Pharmaceuticals FAQs

Fredun Pharmaceuticals share price is ₹1,648 As on 14 March, 2026 | 21:24

The Market Cap of Fredun Pharmaceuticals is ₹778.1 Cr As on 14 March, 2026 | 21:24

The P/E ratio of Fredun Pharmaceuticals is 22.9 As on 14 March, 2026 | 21:24

The PB ratio of Fredun Pharmaceuticals is 4.6 As on 14 March, 2026 | 21:24

Open Free Demat Account

Be a part of 5paisa community - The first listed discount broker of India.

+91

By proceeding, you agree to all T&C*

footer_form

Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.

Q2FY23